PHI-BIS SRL
41.0 FTEThe score of PHI-BIS shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +19 % Equity +90 % Total assets +34 % Headcount (avg FTE) -10 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
PHI-BIS's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €16.2m | ||||
| Net result | 462,055 € | ||||
| Equity | €2.60m | ||||
| Cash | 10,317 € | ||||
| EBITDA | 874,237 € | ||||
| Total assets | €6.23m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 16 Jul 2026
- Year ended 31 Dec 2024filed on 18 Jul 2025
- Year ended 31 Dec 2023filed on 26 Jun 2024
- Year ended 31 Dec 2022filed on 10 Jul 2023
- Year ended 31 Dec 2021filed on 07 Jul 2022
PHI-BIS's financial analysis
- Solvency41.8%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of PHI-BIS
PHI-BIS's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0835.500.392
- VAT number
- BE0835500392
- Peppol
- Registered · 0208:0835500392 · as of 05 Nov 2026
- Legal form
- SRL
- Incorporated
- 12 Apr 2011
- Registered office
- 2390 Malle
- Size
- Small · 41.0 FTE
- Latest accounts
- 2025 · filed on 16 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
PHI-BIS (SRL) has been based in Malle since 2011, active in: retail sale of pharmaceutical products. For 2025, it reports revenue of €16.2m, a net profit of 462,055 € and equity of €2.60m. With 41.0 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 41.8%, below the median of its sector (44.2%).
Companies similar to PHI-BIS
Companies in the same business, of comparable size and area, outside its group.
- APO2370 Retail sale of pharmaceutical products Arendonk · balance sheet €3.86m
- Wille Sandrina Retail sale of pharmaceutical products Grimbergen · balance sheet €4.26m
- Pharmanext Retail sale of pharmaceutical products Ixelles · balance sheet €2.33m
- Apotheek David-Cools Retail sale of pharmaceutical products Herk-de-Stad · balance sheet €2.08m
- Mobiphar Retail sale of pharmaceutical products Zedelgem · balance sheet €1.62m
- Pharmacie Martin-Cosse Retail sale of pharmaceutical products Andenne · balance sheet €2.15m
- Degrofarm Retail sale of pharmaceutical products Deinze · balance sheet €1.47m
- LA Roche Pharma Retail sale of pharmaceutical products La Roche-en-Ardenne · balance sheet €1.97m
Frequently asked questions about PHI-BIS
What is the revenue of PHI-BIS?
According to the 2025 annual accounts filed with the NBB, the revenue of PHI-BIS amounts to 16,192,973 €.
What is the VAT number of PHI-BIS?
In Belgium, the VAT number is the company number prefixed with BE: BE0835500392 for PHI-BIS, if the company is VAT-registered. Its company number (CBE) is 0835.500.392.
Where is the registered office of PHI-BIS?
According to the CBE register, the registered office of PHI-BIS is in 2390 Malle.
What is the equity of PHI-BIS?
At the close of the 2025 financial year, the equity of PHI-BIS amounts to 2,603,384 €, a solvency of 41.8% of total assets.
How many people work at PHI-BIS?
41.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages PHI-BIS?
The register lists 2 active mandates at PHI-BIS. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of PHI-BIS
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →